Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, announced an interim data readout of the phase 1/2a studies of Radspherin for the treatment ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...

Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel: Boulder, Colorado Wednesday, November 13, 2024, 16:00 Hrs [IST] Sonoma Pharmaceuticals, Inc.

Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European ...

ALIGNMT AI, a leading provider of software solutions for AI governance and compliance, announced a strategic collaboration with the Healthcare Financial Management Association (HFMA) to launch a ...